Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia (Q84796148)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

title

Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

main subject

chronic myeloid leukemia

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Kohei Hosokawa

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Shigeki Ohtake

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Eriko Morishita

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Yasushi Terasaki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Toshihiro Fukushima

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Toshiro Kurokawa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Naomi Sugimori

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Sadaya Matano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Kinya Ohata

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Chizuru Saito

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Masaki Yamaguchi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Hirohito Yamazaki

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Yukio Kondo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

Shinji Nakao

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

publication date

15 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

International Journal of Hematology

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

357-363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22893108 AND SRC:MED&resulttype=core&format=json

Practical management of patients with chronic myeloid leukemia receiving imatinib

11 February 2020

cites work

1 reference

12 December 2020

The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000.

1 reference

12 December 2020

Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia

1 reference

12 December 2020

[Descriptive epidemiology of myeloid leukemia]

1 reference

12 December 2020

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

1 reference

12 December 2020

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

12 December 2020

Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients

1 reference

12 December 2020

Effects of lower dose of imatinib to CML patients

1 reference

12 December 2020

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

12 December 2020

Nilotinib as frontline therapy for patients with newly diagnosed Ph chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

1 reference

12 December 2020

[Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].

1 reference

12 December 2020

Drug resistance in cancer: principles of emergence and prevention

1 reference

12 December 2020

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data

1 reference

12 December 2020

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications

1 reference

12 December 2020

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?

1 reference

12 December 2020

Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study

1 reference

12 December 2020

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

12 December 2020

Elderly patients with Ph chronic myelogenous leukemia (CML): results of imatinib mesylate treatment

1 reference

12 December 2020

Dynamics of chronic myeloid leukaemia.

1 reference

12 December 2020

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

1 reference

12 December 2020

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

1 reference

12 December 2020

Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia

1 reference

12 December 2020

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

12 December 2020

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)

1 reference

12 December 2020

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

12 December 2020

Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

1 reference

12 December 2020

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia

1 reference

12 December 2020

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area

1 reference

12 December 2020

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

12 December 2020

Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients

1 reference

12 December 2020

The age incidence of chronic myeloid leukemia can be explained by a one-mutation model

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study

1 reference

12 December 2020

Chronic myeloid leukaemia

1 reference

12 December 2020

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

1 reference

12 December 2020